EN DE
Watch Shouyao Holdings (Beijing) Co. Ltd. A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shouyao Holdings (Beijing) Co. Ltd. A (688197) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Shouyao Holdings (Beijing) Co. Ltd. A stock ¥18.47, price ¥31.36, that is 41.1% below the price, quality 48 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE1000062V6

SH Shouyao Holdings (Beijing) Co. Ltd. A logo Thin data Nov 16, 2026

Shouyao Holdings (Beijing) Co. Ltd. A

688197 · SHG

Far too expensive (fair value 41% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Ranks above peers (4/6) 
Quality 48/100 
Mixed Growth (revenue 5y +4.3 %/yr in CNY) 
Fair value ¥18.47 · Strongly overvalued 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 23/100
Thin data 
Estimate
Watch Shouyao Holdings (Beijing) Co. Ltd. A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥66.15 ¥17.97 Fair Value ¥18.47 Mar 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

56‑month range ¥17.97 – ¥66.15 · fair‑value band ¥13.85 – ¥23.09 · the ¥31.36 price screens above the ¥18.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Shouyao Holdings (Beijing) Co. Ltd. A in your weekly email

Every Wednesday you see whether Shouyao Holdings (Beijing) Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of innovative drugs in China.

Show moreShow less

The company offers drugs for various indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroid cancer, leukemia, and diabetes. The company was founded in 2016 and is headquartered in Beijing, China.

Stock analysis

Shouyao Holdings (Beijing) Co. Ltd. A (688197) currently trades at ¥31.36, while our estimate is ¥18.47, 41% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥13.85 (bear) to ¥23.09 (bull), the price of ¥31.36 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Shouyao Holdings (Beijing) Co. Ltd. A reported revenue of 8.7M CNY in FY2025 versus 13.0M CNY in FY2021, a compound −9.7%/yr. Reported net income was −129M CNY in FY2025.

Key figures

Market cap 4.7B CNY (≈ $701M) Small · EPS (TTM) ¥−0.1300 · Return on equity −12.9% · Return on assets (EBIT) −65.9% (5-year average) · Operating margin −464% · Revenue growth (YoY) +13.0% · Free cash flow −161M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 28% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −41%, 688197 screens richer than that median.

Fair Value

Bear ¥13.85 Fair Value ¥18.47 Bull ¥23.09
Price ¥31.36 · Downside -41.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 77
Are margins and returns getting better?
Cashflow 16
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 7/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+119.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,787.9% (2020) → −1,689.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

688197 screens overvalued: fair value 41% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Shouyao Holdings (Beijing) Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 48 · Above median
Fair Value upside −41.1% · Bottom 25%
Profitability
Return on assets −16.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 13.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.86× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)65 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 688197
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 688197
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs 688197
argenx SE ARGX $950.95 $908.40 −4% vs 688197
CSL Limited CSL A$199.55 A$186.49 −7% vs 688197
Moderna, Inc MRNA $215.27 $135.64 −37% vs 688197
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs 688197
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 688197
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs 688197
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 688197

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shouyao Holdings (Beijing) Co. Ltd. A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shouyao Holdings (Beijing) Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688197

Frequently asked questions

Is Shouyao Holdings (Beijing) Co. Ltd. A (688197) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ¥18.47 versus a price of ¥31.36, about 41% lower (overvalued).
What is the fair value of 688197?
Our estimate for Shouyao Holdings (Beijing) Co. Ltd. A is ¥18.47 (as of Nov 16, 2026), built from audited fundamentals. The current price: ¥31.36.
What is the quality score of 688197?
Shouyao Holdings (Beijing) Co. Ltd. A has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
Our calculated price target is the estimate of ¥18.47 (as of Nov 16, 2026). Cautious scenario ¥13.85, optimistic scenario ¥23.09. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Shouyao Holdings (Beijing) Co. Ltd. A stock forecast for 2026?
Our estimate puts fair value at ¥18.47, about 41% lower versus a price of ¥31.36 (overvalued). Cautious scenario ¥13.85, optimistic scenario ¥23.09. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shouyao Holdings (Beijing) Co. Ltd. A it is ¥18.47 per share (as of Nov 16, 2026), against a price of ¥31.36.
Is Shouyao Holdings (Beijing) Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 688197 trades above its calculated fair value: price ¥31.36, fair value ¥18.47, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688197?
No. The price is what the market pays today (¥31.36); the fair value is what the company's own numbers justify (¥18.47). For Shouyao Holdings (Beijing) Co. Ltd. A the two are ¥12.89 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shouyao Holdings (Beijing) Co. Ltd. A worth?
The market values Shouyao Holdings (Beijing) Co. Ltd. A at about 4.7B CNY (market capitalisation, as of Nov 16, 2026). Per share that is ¥31.36; our models calculate a fair value of ¥18.47 per share.
What do the bullish and bearish scenarios say about 688197?
Our models span a range for Shouyao Holdings (Beijing) Co. Ltd. A: cautious scenario ¥13.85, base ¥18.47, optimistic ¥23.09 per share (as of Nov 16, 2026, price ¥31.36). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
Balance-sheet figures for Shouyao Holdings (Beijing) Co. Ltd. A (as of Nov 16, 2026): return on equity −12.9%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 688197 from its 52-week high?
Shouyao Holdings (Beijing) Co. Ltd. A trades at ¥31.36, about 28% below its 52-week high of ¥43.79 and 3% above the low of ¥30.37 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ¥18.47 is for.
Which stocks are comparable to Shouyao Holdings (Beijing) Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shouyao Holdings (Beijing) Co. Ltd. A stock attractive at the current price?
The data as of Nov 16, 2026: price ¥31.36, calculated fair value ¥18.47 (−41%), Quality Score 48/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Shouyao Holdings (Beijing) Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
The closing price on Nov 17, 2026 was ¥31.36. Our estimate is ¥18.47, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shouyao Holdings (Beijing) Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥23.09). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Shouyao Holdings (Beijing) Co. Ltd. A

How large is the market capitalisation of Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
The market capitalisation of Shouyao Holdings (Beijing) Co. Ltd. A is 4.7B CNY (≈ $701M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
Earnings per share at Shouyao Holdings (Beijing) Co. Ltd. A are ¥−0.1300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
The return on equity (ROE) of Shouyao Holdings (Beijing) Co. Ltd. A is −12.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
On an EBIT basis the return on assets of Shouyao Holdings (Beijing) Co. Ltd. A is −65.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
The operating margin of Shouyao Holdings (Beijing) Co. Ltd. A is −464% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shouyao Holdings (Beijing) Co. Ltd. A (688197)?
Revenue at Shouyao Holdings (Beijing) Co. Ltd. A is growing 13.0% versus a year earlier (3y avg +68.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Shouyao Holdings (Beijing) Co. Ltd. A (688197) generate?
The free cash flow of Shouyao Holdings (Beijing) Co. Ltd. A is −161M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Shouyao Holdings (Beijing) Co. Ltd. A in the live analysis

One click puts Shouyao Holdings (Beijing) Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.